Log in

NASDAQ:RUBYRubius Therapeutics Stock Price, Forecast & News

$5.20
+0.12 (+2.36 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.96
Now: $5.20
$5.61
50-Day Range
$4.91
MA: $5.69
$6.63
52-Week Range
$3.35
Now: $5.20
$14.44
Volume211,874 shs
Average Volume342,953 shs
Market Capitalization$419.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Rubius Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.44 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Employees142
Market Cap$419.99 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$5.20
+0.12 (+2.36 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

How has Rubius Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RUBY shares have decreased by 20.6% and is now trading at $5.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rubius Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Rubius Therapeutics
.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.03.
View Rubius Therapeutics' earnings history
.

What price target have analysts set for RUBY?

6 analysts have issued twelve-month price objectives for Rubius Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect Rubius Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
.

Has Rubius Therapeutics been receiving favorable news coverage?

Media headlines about RUBY stock have trended positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Rubius Therapeutics
.

Are investors shorting Rubius Therapeutics?

Rubius Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 6,960,000 shares, a decrease of 10.3% from the April 30th total of 7,760,000 shares. Based on an average daily volume of 457,100 shares, the short-interest ratio is currently 15.2 days. Approximately 21.7% of the shares of the stock are sold short.
View Rubius Therapeutics' Short Interest
.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 57)
  • Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
  • Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (12.98%), Artal Group S.A. (4.77%), Federated Hermes Inc. (0.75%), Bank of New York Mellon Corp (0.19%), Goldman Sachs Group Inc. (0.15%) and Swiss National Bank (0.09%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen.
View institutional ownership trends for Rubius Therapeutics
.

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Artal Group S.A.. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, and Robert Langer.
View insider buying and selling activity for Rubius Therapeutics
.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, PDT Partners LLC, Virtus ETF Advisers LLC, Trexquant Investment LP, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Tudor Investment Corp Et Al, and State Board of Administration of Florida Retirement System. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $5.20.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $419.99 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.